EP0762122A1 - Biocapteur optique en phase solide à base de streptavidine et biotine - Google Patents

Biocapteur optique en phase solide à base de streptavidine et biotine Download PDF

Info

Publication number
EP0762122A1
EP0762122A1 EP96112608A EP96112608A EP0762122A1 EP 0762122 A1 EP0762122 A1 EP 0762122A1 EP 96112608 A EP96112608 A EP 96112608A EP 96112608 A EP96112608 A EP 96112608A EP 0762122 A1 EP0762122 A1 EP 0762122A1
Authority
EP
European Patent Office
Prior art keywords
streptavidin
biotinylated
antibodies
bound
analyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96112608A
Other languages
German (de)
English (en)
Inventor
Anke Diederich
Matthias Prof. Dr. Lösche
Michael Dr. Völker
Hans-Ulrich Dr. Siegmund
Ludger Dr. Heiliger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of EP0762122A1 publication Critical patent/EP0762122A1/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings

Definitions

  • the present invention relates to an optical biosensor for the detection of dissolved molecules (hereinafter referred to as analytes) which can be labeled with a fluorescent dye and for which a biomolecule specifically recognizing them (referred to below as the receptor) exists.
  • analytes dissolved molecules
  • the receptor a biomolecule specifically recognizing them
  • This is a solid phase sensor with fluorescent dye, which allows the determination of its presence and amount via an energy transfer process to a molecule to be detected and labeled with a second fluorescent dye.
  • the determination of unlabeled analytes is also possible via a displacement or a sandwich reaction.
  • Immunoassays are generally based on the ability of a receptor molecule, for example an antibody, to specifically recognize the structure and molecular organization of a ligand molecule, be it defined by non-polar and / or polar interactions, and to bind this molecule very specifically in such a way.
  • Immunoassays are carried out using various methods. These include the use of various labeling techniques, which are often aimed at quantifying the analyte using radioactive, enzyme-coupled and fluorescent markers (EF Ulman, PL Khanna, Methods in Enzymology, 74 (1981) 28-60).
  • a special case of the latter method is the radiationless fluorescence energy transfer (Förster energy transfer or resonant energy transfer, RET), with which the relative geometric position of two fluorescent dyes can be measured, provided the mutual distance is at most a few nm.
  • RET radiationless fluorescence energy transfer
  • the direct interaction of a receptor / ligand pair can therefore be demonstrated directly (L. Stryer, Annual Reviews in Biochemistry 47 (1978) 819-846). This principle has been mentioned several times in the technology of immunoassays and biosensors (SM Barnard, DR Walt, Science 251 , 927 (1991), EP 150 905, DE 3938598).
  • the present invention relates to the immobilization of biomolecules in molecularly thin, well-ordered layer structures which are particularly suitable for an optical biosensor with the Förster energy transfer as the detection principle.
  • the immobilization of receptors on a solid phase is of crucial importance for biosensors.
  • proteins are mostly bound to surfaces by adsorption or ionic or hydrophobic interactions, or they are coupled via covalent bonds using auxiliary reagents.
  • the activation of glass by 3-aminopropyl-triethoxysilane and the subsequent binding of protein with glutardialdehyde with reduction of the resulting Schiff base by sodium borohydride should be mentioned as a classic example of the latter procedure.
  • the reproducibility of the immobilization is also very bad.
  • Förster energy transfer it has an unfavorable effect that the distance between the energy donor and the acceptor varies irregularly depending on the local surface condition, which generally leads to an increase in the system-related measurement inaccuracy.
  • One way to solve the system-related problems mentioned above is to coat the support with molecularly well-defined films. This can be done by coating the support with a thin film-forming copolymer which, in addition to structure-forming units, contains comonomers with reactive groups in the side chain which are capable of covalently binding the protein to be immobilized, such as e.g. described in DE 43 19 037.
  • a disadvantage of this process is that the number of reactive groups is generally limited by the limited proportion of reactive monomers in the polymer. As a result, the occupancy density of the receptors on the surface is often too low.
  • biotinylated receptors are bound to the layer described under c), which in turn can immobilize antibodies by means of a specific recognition reaction.
  • the present invention accordingly relates to the immobilization of biomolecules, in particular receptors or antibodies, onto a solid phase, the immobilization being permanent and directed in nature and a high occupancy density of the surface being achieved with the receptor.
  • the binding of the analyte is detected by Förster energy transfer and is reproducible by a molecularly well-defined mutual arrangement of energy donor and acceptor and its concentration dependence is regular.
  • the surface is passivated at the same time against unspecific adsorption of proteins. Accordingly, these requirements are met in the present invention and the above-mentioned problems are solved by the immobilization of organic and biological components in molecularly well-defined layers using the natural system biotin / streptavidin.
  • Streptavidin is a protein with four binding sites for biotin (vitamin H). It can therefore serve as a matrix for coupling biotinylated biomolecules. Since the binding constant of biotin with streptavidin is ⁇ 10 15 M -1 , the binding of biotin to streptavidin is almost irreversible.
  • the invention is characterized above all by the use of polycations and polyanions to build up the multilayer.
  • This invention is realized by covering a transparent solid support, usually float glass or quartz glass or organic polymers such as polyester, polycarbonate or polyethylene terephthalate or other transparent, non-fluorescent solids, with a multilayer by means of the self-assembly (SA) technique consecutive physisorption of anionic and cationic polymers.
  • SA self-assembly
  • the polycations are biotinylated with biotin-N-hydroxysuccinimide ester or other reactive esters at 20-80 mol%, preferably 30-70 mol%, particularly preferably 40-60 Mol%, based on the number of equivalents of cationic groups, according to the process described in EP-A 0 472 990.
  • Polycations which are suitable for the invention are, for example, polylysine, polyallylamine, polyvinylamine, poly (4-vinylpyridine), polyacrylamide, polymethacrylamide, polyarginine, polyasparagine, polyglutamine, polyethyleneimine and copolymers of the underlying monomers, preferably polylysine and polyallylamine.
  • N atoms are present as ammonium groups and carry 2 or 3 H atoms
  • biotinylatable polycations polylysine, polyarginine, polyglutamine, polyasparagine, polyacrylamide, polymethacrylamide, polyallylamine and copolymers of the underlying monomers, preferably polylysine and polyallylamine.
  • polyanions examples include polystyrene sulfonate (PSS), polyacrylic acid, polymethacrylic acid, poly (2-acrylamido-2-methyl-1-propanesulfonic acid), polyvinyl sulfonic acid, polyvinyl sulfate, dextran sulfate, cellulose sulfate and copolymers of the underlying monomers, preferably polystyrene sulfonate.
  • Counter cations in the polyanions are, for example, H + , Na + , K + , NH 4 + , preferably Na + or K + .
  • the proportion of the biotinylated cation equivalents can be adapted to the desired requirements via the stoichiometry.
  • the streptavidin After the streptavidin has been immobilized on the biotinylated polymer surface, the streptavidin with its as yet unoccupied binding sites now serves as a matrix for the connection of further biotinylated biomolecules as receptors, in particular for the connection of antibodies.
  • biotinylated protein A or biotinylated protein G to the streptavidin matrix.
  • the biotinylation of protein A using N-hydroxysuccinimide or via other reactive esters is easily possible and familiar to the person skilled in the art.
  • Protein A is a protein from the cell wall of the bacterium Staphylococcus aureus.
  • Optical solid phase biosensors of this type can be used, for example, in the form of test strips.
  • Another embodiment of the immunosensor involves the connection of biotinylated antibodies to the streptavidin matrix.
  • the antibodies can be biotinylated using biotin-N-hydroxysuccinimide or other reactive esters.
  • biotinylation of antibodies which is well known to the person skilled in the art, has the disadvantage that the biotinylation is not region-specific.
  • Some of the IgG molecules are also biotinylated at or near the antigen binding site, so that they are sterically blocked and the immunological activity of the antibodies and thus the sensitivity of the sensor decrease.
  • biotin derivatives with hydrazide reactive groups are used which react with oxidized antibodies.
  • the carbohydrates located on the F c part of the IgGs are cleaved in a reaction known to the person skilled in the art (glycol cleavage) and aldehydes are generated.
  • the biotin groups are thus linked region-specifically to the F c part of the antibodies.
  • the biotinylated antibodies are coupled to the streptavidin matrix and complete the test strip surface of the immunosensor without the need for coupling via biotinylated protein A.
  • the test strip is now able to recognize and quantify the analyte provided with a suitable acceptor dye F2 (e.g. rhodamine isothiocyanate) by interaction of the receptor, in particular the antibody, with the analyte.
  • F2 e.g. rhodamine isothiocyanate
  • the analyte is detected by simply bringing the coated carrier into contact with the solution in which a molecule is suspected to be an analyte (sample solution) and subsequent fluorescence measurement.
  • the fluorescence of the donor (F1) and the acceptor (F2) dye is measured.
  • the intensity of the acceptor fluorescence will increase due to the Förster energy transfer and that of the donor will decrease compared to the unbound state.
  • the test strip is first equilibrated with an acceptably labeled analog of the analyte in question. In this state, the acceptor fluorescence of F2 then outweighs the donor fluorescence of F1.
  • the Förster energy transfer will be interrupted after the displacement reaction, so that an increase in the donor fluorescence of F1 and a decrease in the acceptor fluorescence of F2 signalize the binding of the unlabeled analyte. In both cases, the change in acceptor and donor fluorescence is clearly related to the concentration of the analyte.
  • the Förster energy transfer can be measured in conventional fluorescence spectrometers, but also in specially designed devices for an energy transfer immunosensor. The concentration of the analyte in the analysis liquid can then be determined by means of suitable calibration curves.
  • a specifically binding molecule labeled with the fluorescent dye F2 is added in known amount to an analysis solution in which the analyte to be detected is suspected competed.
  • the concentration of the analyte to be detected is then measured by the dependence of the fluorescence intensities on F2 or on F1 or the ratio of the two intensities.
  • Another embodiment of the immunosensor according to the invention includes the connection of the donor dye F1 to the receptor, preferably the antibody, preferably via hydrazide reactive groups to oxidized antibodies in the form described above.
  • the efficiency of Förster energy transfer by reducing the average distance between donor (F1) and acceptor (F2) dye, which can be used to increase the sensitivity of the test method.
  • the measurement shows that the surface is covered with an interface layer of organic material that has grown regularly in the various preparation steps and that the preparation remains molecularly smooth in each step.
  • the carrier cleaning was carried out according to a standard procedure (W. Kern, DA Puotinen, RCA Review, 31 (1970), 187)
  • the carrier was placed in a solution of biotinylated polylysine hydrobromide (PLB) (5 mg / 10 ml in 0.4 M NaCl) for 20 minutes and then washed and dried again.
  • PLB biotinylated polylysine hydrobromide
  • the carrier coated with protein A was immersed in a rabbit IgG solution (specificity: anti-mouse IgG, 5 10 -7 mol / l, PBS buffer as above) and washed three times with the pure buffer. The carrier was kept in PBS buffer until the antigen was bound.
  • FIG. 2 shows X-ray reflectograms which were measured between the different adsorption steps during the preparation of a test strip (silicon substrate) (dry sample).
  • FIG. 3 shows a representative result for a preparation which was produced using the technology presented here.
  • Samples were prepared on float glass as described above. 10 mg / ml BSA was dissolved in PBS buffer. This protein solution was used to prepare a dilution series of the RITC-labeled antigen. In this series of dilutions the concentration of the antigen was between 2.5 10 -9 and 5 10 -6 mol / l.
  • the carriers were placed in the solution of a specific antigen concentration for about 40 minutes and then washed 5 times for about 1 minute in a PBS buffer (buffer composition as above) mixed with 0.1% TWEEN-20. The carriers were blown dry in a stream of nitrogen and stored in the dark at 4 ° C. until measured.
  • supports were coated in the same sequence up to and including the streptavidin layer (but without protein A and IgG layers) and placed in an antigen-containing solution of the dilution series for about 40 minutes and, as above described, washed and dried.
  • sample and reference carriers were measured both in a conventional fluorescence spectrometer and in a specially designed device for measuring the fluorescence energy transfer in the dry state.
  • Figure 4 shows representative results.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
EP96112608A 1995-08-16 1996-08-05 Biocapteur optique en phase solide à base de streptavidine et biotine Withdrawn EP0762122A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1995130078 DE19530078A1 (de) 1995-08-16 1995-08-16 Optischer Festphasenbiosensor auf Basis von Streptavidin und Biotin
DE19530078 1995-08-16

Publications (1)

Publication Number Publication Date
EP0762122A1 true EP0762122A1 (fr) 1997-03-12

Family

ID=7769594

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96112608A Withdrawn EP0762122A1 (fr) 1995-08-16 1996-08-05 Biocapteur optique en phase solide à base de streptavidine et biotine

Country Status (4)

Country Link
EP (1) EP0762122A1 (fr)
JP (1) JPH0954094A (fr)
CA (1) CA2183204A1 (fr)
DE (1) DE19530078A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055864A3 (fr) * 1997-06-06 1999-03-04 Biotez Berlin Buch Gmbh Surfaces revetues de streptavidine/avidine
WO1999045142A3 (fr) * 1998-03-03 1999-10-28 November Ag Molekulare Medizin Agent et procede pour mettre la presence de substances chimiques en evidence
WO2000065352A1 (fr) * 1999-04-28 2000-11-02 Eidgenossisch Technische Hochschule Zurich Revetements polyioniques dans des dispositifs d'analyse et de detection
WO2000077496A1 (fr) * 1999-06-14 2000-12-21 November Aktiengesellschaft Gesellschaft Fuer Molekulare Medizin Procede et dispositif d'identification d'un polymere
DE10035451A1 (de) * 2000-07-19 2002-02-07 November Ag Molekulare Medizin Verfahren und Vorrichtung zur Identifizierung einer Polymersequenz
CN100339712C (zh) * 2002-09-13 2007-09-26 日立化成工业株式会社 固定化载体和固相
US7316845B2 (en) 1997-04-21 2008-01-08 California Institute Of Technology Multifunctional polymeric tissue coatings
US7855068B2 (en) * 2002-04-25 2010-12-21 Semibio Holdings Limited Methods and kits for detecting a target cell
WO2020095083A1 (fr) 2018-11-05 2020-05-14 Toray Films Europe Procédé spectroscopique de fluorescence
CN113533282A (zh) * 2021-07-15 2021-10-22 中国科学院苏州生物医学工程技术研究所 一种基于均相时间分辨荧光的生物素定量测定方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2335490B (en) * 1998-03-20 2003-05-14 Ortho Clinical Diagnostics An assay surface that permits an analyte releasiing step
NL1014816C2 (nl) * 2000-03-31 2001-10-02 Tno Werkwijze voor het bepalen van binding met natuurlijke receptoren.
WO2001079848A1 (fr) * 2000-03-31 2001-10-25 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Procede pour determiner la liaison avec des recepteurs naturels
DE10148102B4 (de) * 2001-09-28 2006-03-30 Biotez Berlin-Buch Gmbh Biochip zum quantitativen fotometrischen Nachweis von Biomolekülen, seine Verwendung und Verfahren zum quantitativen Nachweis von Biomolekülen durch fotometrisches Erfassen einer Farbreaktion
JP2009265062A (ja) * 2008-04-30 2009-11-12 Yasuro Niitome 分析用チップとその製造方法およびその分析方法
JP2013120120A (ja) * 2011-12-07 2013-06-17 Konica Minolta Medical & Graphic Inc ラテラルフロー型クロマト法用テストストリップ、およびそれを用いたアナライトの検出または定量方法
WO2014132692A1 (fr) * 2013-02-28 2014-09-04 株式会社村田製作所 Dispositif de mesure et son procédé de fabrication
JP6422075B2 (ja) * 2014-09-24 2018-11-14 太陽誘電株式会社 組成物及び組成物を利用したモーター蛋白デバイス
US10527614B2 (en) 2015-11-09 2020-01-07 Bio-Rad Laboratories, Inc. Assays using avidin and biotin
CN121762450B (zh) * 2026-03-03 2026-05-29 德路通（石家庄）生物科技有限公司 一种回音壁模式传感器及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009408A1 (fr) * 1988-03-29 1989-10-05 Ares-Serono Research & Development Limited Partner Procede d'analyse
EP0405578A2 (fr) * 1989-06-29 1991-01-02 Nippon Shoji Kabushiki Kaisha Immunoessai enzymatique pour détecter les antigènes et phase solide pour sa mise en oeuvre
EP0429907A2 (fr) * 1989-11-21 1991-06-05 Bayer Ag Biocapteur optique
EP0561239A1 (fr) * 1992-03-18 1993-09-22 Bayer Ag Biocapteur optique en phase solide, avec des couches polyioniques fluorescentes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009408A1 (fr) * 1988-03-29 1989-10-05 Ares-Serono Research & Development Limited Partner Procede d'analyse
EP0405578A2 (fr) * 1989-06-29 1991-01-02 Nippon Shoji Kabushiki Kaisha Immunoessai enzymatique pour détecter les antigènes et phase solide pour sa mise en oeuvre
EP0429907A2 (fr) * 1989-11-21 1991-06-05 Bayer Ag Biocapteur optique
EP0561239A1 (fr) * 1992-03-18 1993-09-22 Bayer Ag Biocapteur optique en phase solide, avec des couches polyioniques fluorescentes

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7316845B2 (en) 1997-04-21 2008-01-08 California Institute Of Technology Multifunctional polymeric tissue coatings
WO1998055864A3 (fr) * 1997-06-06 1999-03-04 Biotez Berlin Buch Gmbh Surfaces revetues de streptavidine/avidine
US6468752B1 (en) 1998-03-03 2002-10-22 November Aktiengesellschaft Gesellschaft Fur Molekulare Medizin Agent and method for detecting chemical substances
WO1999045142A3 (fr) * 1998-03-03 1999-10-28 November Ag Molekulare Medizin Agent et procede pour mettre la presence de substances chimiques en evidence
WO2000065352A1 (fr) * 1999-04-28 2000-11-02 Eidgenossisch Technische Hochschule Zurich Revetements polyioniques dans des dispositifs d'analyse et de detection
WO2000077496A1 (fr) * 1999-06-14 2000-12-21 November Aktiengesellschaft Gesellschaft Fuer Molekulare Medizin Procede et dispositif d'identification d'un polymere
US7067253B1 (en) 1999-06-14 2006-06-27 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Method and device for identifying a polymer
DE10035451C2 (de) * 2000-07-19 2002-12-05 November Ag Molekulare Medizin Verfahren und Vorrichtung zur Identifizierung einer Polymersequenz
DE10035451A1 (de) * 2000-07-19 2002-02-07 November Ag Molekulare Medizin Verfahren und Vorrichtung zur Identifizierung einer Polymersequenz
US7855068B2 (en) * 2002-04-25 2010-12-21 Semibio Holdings Limited Methods and kits for detecting a target cell
CN100339712C (zh) * 2002-09-13 2007-09-26 日立化成工业株式会社 固定化载体和固相
WO2020095083A1 (fr) 2018-11-05 2020-05-14 Toray Films Europe Procédé spectroscopique de fluorescence
US11733097B2 (en) 2018-11-05 2023-08-22 Toray Films Europe Fluorescence spectroscopic method using polyester composition containing additive to prevent oxidative degradation, and substrate, optical filter, security document, and sensor device containing the polyester composition
CN113533282A (zh) * 2021-07-15 2021-10-22 中国科学院苏州生物医学工程技术研究所 一种基于均相时间分辨荧光的生物素定量测定方法
CN113533282B (zh) * 2021-07-15 2024-05-28 中国科学院苏州生物医学工程技术研究所 一种基于均相时间分辨荧光的生物素定量测定方法

Also Published As

Publication number Publication date
DE19530078A1 (de) 1997-02-20
CA2183204A1 (fr) 1997-02-17
JPH0954094A (ja) 1997-02-25

Similar Documents

Publication Publication Date Title
DE19530078A1 (de) Optischer Festphasenbiosensor auf Basis von Streptavidin und Biotin
DE69121021T2 (de) Bindungsnachweisverfahren mit Konjugatrückgewinnung
EP0561239B1 (fr) Biocapteur optique en phase solide, avec des couches polyioniques fluorescentes
EP0429907B1 (fr) Biocapteur optique
Di Nardo et al. A fluorescent immunochromatographic strip test using Quantum Dots for fumonisins detection
DE69731306T2 (de) Verfahren und kit zur bestimmung eines analyts mittels massenbestimmung
DE69635607T2 (de) Liposom-verstärkter immunoaggregations-test und testvorrichtung
DE69719742T2 (de) Biosensor-vorrichtung und verfahren
EP0397113B1 (fr) Méthode de détection de substances capables de se lier spécifiquement dans les fluides corporels
DE69412137T2 (de) Sensoreinrichtung zum sandwichtest
EP0363942B1 (fr) Procédé pour la détermination d'une substance liante spécifique
DE69116236T2 (de) Bestimmung von Analyten, die Bindungsstellen für mindestens zwei Bindungsgruppen haben
DE69930404T2 (de) Methode zum nachweis von analyten
US5650333A (en) Immunoassay method and kit using superaggregated complex
JPH05209886A (ja) 同時較正不均質イムノアツセイ
Nilsson et al. Thin-layer immunoaffinity chromatography with bar code quantitation of C-reactive protein
Garcinuno et al. Development of a fluoroimmunosensor for theophylline using immobilised antibody
EP2167965B1 (fr) Procédé de détection d'analytes
DE69328727T2 (de) Immunologisches nachweisverfahren unter verwendung von zwei bestimmbaren markern
EP1512010B1 (fr) Biocapteur universel et procedes d'utilisation
JP4545869B2 (ja) 多孔性フィルタを用いる生理活性試料物質の測定方法
DE69220080T2 (de) Reagenzzusammensetzung in form von benutzer-einheiten für spezifische bindungstests
DE69332454T2 (de) Trennverfahren
CN103353523B (zh) 磷光二氧化硅纳米颗粒标记的免疫层析方法及其检测试纸
DE69127628T2 (de) Hochempfindlicher optischer Immunoassay durch Gebrauch von Enzymmarkierten Reagenz

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE DE FR GB IT LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19970821